M. Vanessa Pérez Gómez-rekin lankidetzan egindako argitalpenak (3)

2023

  1. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

2022

  1. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

2016

  1. Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis

    Clinical Kidney Journal, Vol. 9, Núm. 3, pp. 381-386